Skip to Content

Epoprostenol Dosage

Applies to the following strength(s): 0.5 mg ; 1.5 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Pulmonary Hypertension

Acute Dose Ranging: 2 ng/kg/min and increased in increments of 2 ng/kg/min every 15 minutes or longer until dose-limiting pharmacologic effects are elicited.
The mean maximum dose which did not elicit dose-limiting pharmacologic effects was 8.6 ng/kg/min.
Continuous Chronic Infusion: 4 ng/kg/min less than the maximum tolerated infusion rate determined during acute dose ranging.
If the maximum tolerated infusion rate is less than 5 ng/kg/min, the chronic infusion should be started at one-half the maximum tolerated infusion rate. During clinical trials, the mean initial chronic infusion rate was 5 ng/kg/min.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Changes in the chronic infusion rate should be based on persistence, recurrence, or worsening of the patient's symptoms of PPH and the occurrence of adverse events due to excessive doses of epoprostenol. In general, increases in dose from the initial chronic dose should be expected. In the controlled 12 week trial, for example, the dose increased from a mean starting dose of 5.2 ng/kg/min (4 ng/kg/min less than the new tolerated dose) to 9.2 ng/kg/min by the end of week 12, just 1.6 ng/kg/min less than the mean non- tolerated dose.
Increments in dose should be considered if symptoms of PPH persist or recur after improving. The infusion should be increased by 1 to 2 ng/kg/min increments at intervals sufficient to allow assessment of clinical response. These intervals should be at least 15 minutes. Following establishment of a new chronic infusion rate, the patient should be observed, and standing and supine blood pressure and heart rate monitored for several hours to ensure that the new dose is tolerated.
During chronic infusion, the occurrence of dose-related pharmacological events similar to those observed during acute dose ranging may necessitate a decrease in infusion rate, but the adverse event may occasionally resolve without dosage adjustment. Dosage decreases should be made gradually in 2 ng/kg/min decrements every 15 minutes or longer until the dose-limiting effects resolve.


The most common dose-limiting pharmacologic effects (occurring in 1% or more of patients) during dose ranging are nausea, vomiting, headache, hypotension, and flushing, but also include chest pain, anxiety, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, and tachycardia.

Abrupt withdrawal of epoprostenol or sudden large reductions in infusion rates should be avoided. Except in life-threatening situations (e.g., unconsciousness, collapse, etc.).

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

In patients receiving lung transplants, doses of epoprostenol were tapered after the initiation of cardiopulmonary bypass.